Literature DB >> 25751471

Validity of Montreal Cognitive Assessment in non-english speaking patients with Parkinson's disease.

Syam Krishnan1, Sunitha Justus, Radhamani Meluveettil, Ramshekhar N Menon, Sankara P Sarma, Asha Kishore.   

Abstract

BACKGROUND: The Montreal Cognitive Assessment is a brief and easy screening tool for accurately testing cognitive dysfunction in Parkinson's disease. We tested its validity for use in non-English (Malayalam) speaking patients with Parkinson's disease.
MATERIALS AND METHODS: We developed a Malayalam (a south-Indian language) version of Montreal Cognitive Assessment and applied to 70 patients with Parkinson's disease and 60 age- and education-matched healthy controls. Metric properties were assessed, and the scores were compared with the performance in validated Malayalam versions of Mini Mental Status Examination and Addenbrooke's Cognitive Examination.
RESULTS: The Montreal Cognitive Assessment-Malayalam showed good internal consistency and test-retest reliability and its scores correlated with Mini Mental Status Examination (patients: R = 0.70; P < 0.001; healthy controls: R = 0.26; P = 0.04) and Addenbrooke's Cognitive Examination (patients: R = 0.8; P < 0.001; healthy controls: R = 0.52; P < 0.001) scores.
CONCLUSION: This study establishes the reliability of cross-cultural adaptation of Montreal Cognitive Assessment for assessing cognition in Malayalam-speaking Parkinson's disease patients for early screening and potential future interventions for cognitive dysfunction.

Entities:  

Mesh:

Year:  2015        PMID: 25751471     DOI: 10.4103/0028-3886.152637

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  8 in total

1.  Cognitive outcome following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease-a comparative observational study in Indian patients.

Authors:  Kshiteeja Jain; Remya Ramesh; Syam Krishnan; Krishnakumar Kesavapisharady; K P Divya; Sankara P Sarma; Asha Kishore
Journal:  Acta Neurol Belg       Date:  2021-08-26       Impact factor: 2.396

2.  The relationship between cognitive functioning, age and employment in people with severe mental illnesses in an urban area in India: A longitudinal study.

Authors:  Chitra Khare; Kim T Mueser; Susan R McGurk
Journal:  Schizophr Res Cogn       Date:  2022-05-03

3.  Cultural adaptation of Alzheimer's disease assessment scale-cognitive subscale for use in India and validation of the Tamil version for South Indian population.

Authors:  Monisha Lakshminarayanan; Sridhar Vaitheswaran; Nivedhitha Srinivasan; Gayathri Nagarajan; Ahalya Ganesh; Kunnukatil S Shaji; Mina Chandra; Murali Krishna; Aimee Spector
Journal:  Aging Ment Health       Date:  2021-01-25       Impact factor: 3.514

Review 4.  Status of Cognitive Testing of Adults in India.

Authors:  A P Porrselvi; V Shankar
Journal:  Ann Indian Acad Neurol       Date:  2017 Oct-Dec       Impact factor: 1.383

5.  Correlation of cognitive functions with emotional dysregulation in alcohol dependence: A preliminary study.

Authors:  Dushad Ram; Manju George; Basawanna Gowdappa
Journal:  Indian J Psychiatry       Date:  2018 Jul-Sep       Impact factor: 1.759

6.  Translation, Cultural Adaptation, and Validation of the Hiligaynon Montreal Cognitive Assessment Tool (MoCA-Hil) Among Patients With X-Linked Dystonia Parkinsonism (XDP).

Authors:  Nicole B Aliling; Adovich S Rivera; Roland Dominic G Jamora
Journal:  Front Neurol       Date:  2019-11-28       Impact factor: 4.003

Review 7.  Developing guidelines for the translation and cultural adaptation of the Montreal Cognitive Assessment: scoping review and qualitative synthesis.

Authors:  Ghazn Khan; Nadine Mirza; Waquas Waheed
Journal:  BJPsych Open       Date:  2022-01-07

8.  A novel method for evaluating brain function and microstructural changes in Parkinson's disease.

Authors:  Ming-Fang Jiang; Feng Shi; Guang-Ming Niu; Sheng-Hui Xie; Sheng-Yuan Yu
Journal:  Neural Regen Res       Date:  2015-12       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.